

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

**RESIGNATION OF SENIOR MANAGEMENT AND JOINT COMPANY
SECRETARY;
AND
RE-DESIGNATION OF AN EXECUTIVE DIRECTOR TO A
NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) announces that Dr. JIANG Mingyu (“**Dr. Jiang**”), an executive Director, vice president, Board secretary and joint company secretary (the “**Joint Company Secretary**”) of the Company, has notified the Company that he will resign from his position as vice-president, Board secretary and Joint Company Secretary with effect from June 13, 2025 in order to devote more time to pursue his other business engagements.

The Board further announces that Dr. Jiang would be re-designated from an executive Director to a non-executive Director with effect from June 13, 2025.

The biographical details of Dr. Jiang are set out below:

Dr. Jiang, aged 37, joined our Group in July 2019 as our vice president and Board secretary. He has more than 12 years of experience in audits, risk management and equity research. From October 2009 to November 2011, he worked at KPMG Huazhen LLP (畢馬威華振會計師事務所), an accounting firm. From December 2011 to January 2013, he worked at KPMG Advisory (China) Co., Ltd. (畢馬威企業諮詢(中國)有限公司), a consultancy firm. From June 2015 to March 2018, he worked at Shanghai Pudong Science & Technology Investment Co., Ltd. (上海浦東科技投資有限公司), an investment and private equity firm. From March 2018 to July 2019, he was a senior analyst at Zheshang Securities Co., Ltd. (浙商證券股份有限公司) (stock code: 601878), a securities company listed on the Shanghai Stock Exchange.

Dr. Jiang obtained his bachelor's degree in financial management from Shanghai University of International Business and Economics (上海對外經貿大學) in Shanghai in July 2009. He obtained his master's degree in global finance from Fordham University in New York in May 2014. He further obtained his doctor's degree in pharmacoeconomics at China Pharmaceutical University (中國藥科大學) in Jiangsu in June 2024.

Dr. Jiang has been certified as a financial risk manager by the Global Association of Risk Professionals since September 2012.

The Company will enter into a letter of appointment of non-executive Director with Dr. Jiang in respect of his re-designation to a non-executive Director for a term commencing from June 13, 2025 until the expiry of the term of office of the second session of the Board. Dr. Jiang is not proposed to receive any fixed remuneration for serving as a non-executive Director.

Dr. Jiang has confirmed that he has no disagreement with the Board and is not aware of other matters about his resignation as vice-president, Board secretary, and Joint Company Secretary and the re-designation to a non-executive Director that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). As of the date of this announcement, Dr. Jiang is not interested in any shares of the Company and he will remain subject to retirement by rotation and is eligible for re-election at a general meeting upon expiry of his term of office pursuant to the articles of association of the Company and the Rules Governing the Listing of Securities of the Stock Exchange (the “**Listing Rules**”).

Save as disclosed above, Dr. Jiang confirmed that (i) he did not hold any position within the Group or any directorship of other public companies in the last three years; (ii) he does not have any relationship with any Director, supervisor, senior management, substantial or controlling shareholder of the Company; and (iii) he does not have any interest in the shares of the Company within the meaning of Part XV of the SFO (Cap. 571 of Laws of Hong Kong). There is no other information which is discloseable nor is Dr. Jiang involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Dr. Jiang that need to be brought to the attention of the Shareholders.

The Board would like to express its sincere gratitude to Dr. Jiang for his valuable contributions during his tenure of office as a vice president, Board secretary, executive Director and Joint Company Secretary.

Upon Dr. Jiang’s resignation taking effect on June 13, 2025, the other Joint Company Secretary, Ms. Wong Wing Yee will remain in office and act as the sole company secretary of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, May 27, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng and Dr. JIANG Mingyu as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying and Mr. HE Chao as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.